Company / Income Tax
Neurocrine Biosciences Income Tax History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Income Tax
$226.8M
FY2025
5-year range
$11.8M / $226.8M
FY2021-FY2025
Trend
+56.7%
vs FY2024
Sector context
#16 of 202
Health Care
What the data says
Among 202 Health Care companies, Neurocrine Biosciences is in the bottom 8% for income tax. Income Tax has increased for 5 consecutive years, from -$301M in FY2020 to $227M in FY2025.
Based on SEC 10-K filings.
$227M in FY2025 with a 3-year CAGR of +56.3%. Top quartile in the Health Care sector.
Increased from $82M to $227M over the past 2 years.
Health Care sector context is included.
Income Tax over time
Growth rates
- 3-Year CAGR
- +56.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 202This company $226.8M Sector average $119.7M
▼
+89.4% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's income tax has grown for 5 consecutive years.
- 3-year CAGR of +56.3%, indicating consistent growth.
- In FY2025, income tax increased 56.7% year-over-year.
- Ranks #16 out of 202 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Income TaxValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $226.8M | +56.7% |
| FY2024 | $144.7M | +75.6% |
| FY2023 | $82.4M | +38.7% |
| FY2022 | $59.4M | +403.4% |
| FY2021 | $11.8M | +103.9% |
| FY2020 | -$300.6M | -3264.2% |
| FY2019 | $9.5M | +1257.1% |
| FY2018 | $700.0K | - |
| FY2017 | $0 | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026